Male infertility is a growing global concern with increasing prevalence in both developing and developed nations. While many associations between environmental factors and male infertility have been explored, the relationship between sleep deprivation and male infertility remains underexplored. This narrative review examines the reported effects of sleep deprivation on the Hypothalamic––Gonadal (HPG) axis, Hypothalamic–Pituitary–Adrenal (HPA) axis, oxidative stress, and testicular function, and their consequential effects on male infertility. Disruption of the HPG axis results in altered follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, leading to fluctuation in testosterone levels, negatively affecting spermatogenesis and other critical reproductive processes. Activation of the HPA axis, often due to stress, elevates cortisol levels, which, in turn, suppresses gonadotropin-releasing hormone (GnRH), impairing reproductive function. Reactive oxidative species (ROS) accumulate in periods of oxidative stress and have been shown to damage sperm and reduce their quality. The blood–testis barrier (BTB) is disrupted in states of sleep deprivation, leading to decreased sperm quality. A literature review was conducted using PubMed and Google Scholar to assess peer-reviewed studies from 1990 to 2024, revealing a complex interplay between sleep deprivation and male reproductive dysfunction. While existing studies support a link between sleep disturbances and hormonal dysregulation, further research is needed to establish causal relationships and identify potential therapeutic interventions. Addressing sleep deprivation may represent a modifiable factor in improving male fertility outcomes.

Male infertility is a growing global concern with increasing prevalence in both developing and developed nations. While many associations between environmental factors and male infertility have been explored, the relationship between sleep deprivation and male infertility remains underexplored. This narrative review examines the reported effects of sleep deprivation on the Hypothalamic-Pituitary-Gonadal (HPG) axis, Hypothalamic-Pituitary-Adrenal (HPA) axis, oxidative stress, and testicular function, and their consequential effects on male infertility. Disruption of the HPG axis results in altered FSH and LH levels, leading to fluctuation in testosterone levels, negatively affecting spermatogenesis and other critical reproductive processes. Activation of the HPA axis, often due to stress, elevates cortisol levels, which, in turn, suppresses gonadotropin-releasing hormone (GnRH), impairing reproductive function. Reactive oxidative species accumulate in periods of oxidative stress and have been shown to damage sperm and reduce their quality. The blood-testis-barrier (BTB) is disrupted in states of sleep deprivation, leading to decreased sperm quality. A literature review was conducted using PubMed and Google Scholar to assess peer-reviewed studies from 1990 to 2024, revealing a complex interplay between sleep deprivation and male reproductive dysfunction. While existing studies support a link between sleep disturbances and hormonal dysregulation, further research is needed to establish causal relationships and identify potential therapeutic interventions. Addressing sleep deprivation may represent a modifiable factor in improving male fertility outcomes.

Prolonged wait times in psychiatric care (in the emergency department, outpatient setting, or between diagnosis and treatment initiation) have been associated with worsening clinical outcomes. This mini-review explores how wait times in psychiatric care contribute to worsening symptoms and emphasizes the need for earlier intervention. Psychiatric patients admitted through the emergency department stayed in the emergency department 3.2 times longer compared to nonpsychiatric admission. Following in-patient psychiatric care, patients are typically referred to outpatient visits. From 2011 to 2022 an increase in the median waiting time for outpatient psychiatic visits from 15 to 50 days was reported. After outpatient visits, patients still experience delays in their treatment initiation. Longer intervals between diagnosis and treatment initiation have been associated with worsening clinical outcomes. All these delays in psychiatric care highlight critical periods where early intervention can improve symptom progression and clinical outcomes.

Persons experiencing homelessness (PEH) face disproportionately high rates of psychiatric illness and hospitalization, with mental illness prevalence reported as high as 76.2%—significantly higher than in the general population. Psychiatric treatment for PEH is often hindered by systemic barriers to care, including medication nonadherence stemming from fragmented healthcare delivery, stigma, transportation challenges, and unstable housing. This discontinuity contributes to elevated readmission rates, with studies showing 30-day psychiatric readmission rates up to 2.04 times higher for unhoused individuals. Medication access is further complicated by inappropriate prescribing patterns and difficulty in maintaining treatment regimens for chronic mental illnesses such as schizophrenia and bipolar disorder. Multifactorial barriers—spanning patient-level, treatment-related, and structural factors—worsen adherence. Evidence-based interventions such as Assertive Community Treatment, Customized Adherence Enhancement with long-acting injectables, and Housing First models have shown success in improving treatment continuity and reducing psychiatric symptomatology. Emerging solutions like street medicine and mobile outreach deliver low-barrier care directly to shelters and encampments. Addressing psychiatric medication adherence among PEH is not only a clinical priority but a public health imperative, requiring integrated, compassionate, and housing-informed care models.

Five billion people, more than half of humanity, lack access to safe, affordable surgical care. While conventional surgical infrastructure requires decades and trillions of dollars to replicate in low-resource settings, emerging non-incisional technologies offer an alternative paradigm. Histotripsy is a focused ultrasound modality that mechanically destroys tissue without incisions, anesthesia, or prolonged hospitalization. It represents a potential leapfrog technology for addressing the global surgical divide. This editorial examines the technical, economic, and implementation considerations that position histotripsy as a transformative intervention for global surgical equity. We propose a framework for accelerated deployment and outline the policy, research, and financing mechanisms required to realize this potential within a generation.